Abstract
C5a and C5a des Arg are potent complement-derived mediators that bind receptors on peripheral blood leukocytes and tissue-specific cellular elements to elicit and amplify inflammatory and immunomodulatory reactions. To study the interactions of C5a and C5a des Arg with these cells, fluorescein conjugates of these ligands were prepared by a new technique and their binding to monocytes, neutrophils, platelets, and endothelial cells was studied with flow cytometry. Fluoresceinated C5a produced neutrophil myeloperoxidase release and chemotaxis and also bound rabbit anti-C5a antibody much like native anaphylatoxin; likewise, fluoresceinated C5a des Arg demonstrated retention of biologic and antigenic activities. Both fluorescein-conjugated C5a and C5a des Arg bound to monocytes and neutrophils in a concentration-dependent, saturable, and homogeneous manner, but 10- to 15-fold higher concentrations of C5a des Arg were required to attain saturable binding of these leukocytes. Ligand binding was specifically inhibited by native purified human C5a in a concentration-dependent manner, while it was unaffected by C3a or N-formyl-methionyl-leucyl-phenylalanine-lysine. There was no evidence of a C5a receptor-negative subpopulation of monocyt...Continue Reading
References
Sep 1, 1979·The Journal of Clinical Investigation·M M GlovskyB W Erickson
Jun 1, 1978·Inflammation·R O Webster, P M Henson
Aug 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·D E Chenoweth, T E Hugli
Oct 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·J P GorskiH J Müller-Eberhard
Jan 1, 1978·Advances in Immunology·T E Hugli, H J Müller-Eberhard
Sep 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·H TowbinJ Gordon
Feb 1, 1985·The Journal of Clinical Investigation·K B YanceyT J Lawley
Apr 15, 1987·Thrombosis Research·K N ProdouzJ C Fratantoni
Jul 1, 1988·The Journal of Experimental Medicine·S OkusawaJ A Gelfand
Apr 1, 1987·The American Journal of Dermatopathology·K B YanceyT J Lawley
Apr 17, 1986·Journal of Immunological Methods·L RenferK B Yancey
Jan 1, 1986·Complement·T E Hugli
Apr 1, 1987·The Journal of Investigative Dermatology·K B YanceyT J Lawley
May 1, 1973·The Journal of Experimental Medicine·E H Vallota, H J Müller-Eberhard
Feb 1, 1973·The Journal of Experimental Medicine·S H Zigmond, J G Hirsch
Aug 15, 1970·Nature·U K Laemmli
Jun 1, 1980·Immunopharmacology·R O WebsterP M Henson
Sep 1, 1982·The Journal of Experimental Medicine·M G GoodmanW O Weigle
Jan 1, 1980·Journal of Immunological Methods·L HarvathE J Leonard
Jul 1, 1982·The Journal of Experimental Medicine·D E ChenowethW O Weigle
Feb 19, 1981·Nature·C V Wedmore, T J Williams
Citations
Jul 28, 1995·The Journal of Biological Chemistry·L F KolakowskiN P Gerard
Aug 9, 2001·Experimental Dermatology·U MrowietzJ M Schröder
Mar 25, 2005·Vox Sanguinis·C P TurnerR Cardigan
Apr 25, 2014·Cell Biochemistry and Biophysics·F M de BeerW K Lagrand
Feb 13, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·S M DrouinR A Wetsel
Jan 1, 2012·Biosensors·Reena HalaiMatthew A Cooper
Jan 1, 2004·American Journal of Respiratory and Critical Care Medicine·Jung-Won ParkErwin W Gelfand
Apr 29, 2011·PloS One·Catherine MartelArnaud Bonnefoy
Apr 4, 2021·Cancers·Rebecca M O'BrienNiamh Lynam-Lennon
Nov 14, 2001·Biochemistry·S A CainP N Monk
Apr 29, 1999·Clinical Immunology : the Official Journal of the Clinical Immunology Society·D J BirminghamA A Creasey
Jun 17, 1998·Journal of Neuroimmunology·F LahrtzA Fontana
May 30, 2001·Biochemical Pharmacology·S A CainP N Monk
Apr 28, 1994·Biochimica Et Biophysica Acta·P N MonkL J Partridge
Jul 28, 1999·Biochemistry·T CrassP N Monk